Atrasentan
Sponsors
Novartis Pharma AG, Abbott, Massachusetts General Hospital, Mayo Clinic, AbbVie (prior sponsor, Abbott)
Conditions
AdenocarcinomaAdenocarcinoma of the ProstateAlport SyndromeChronic Kidney DiseaseDiabetesDiabetic Kidney DiseaseDiabetic NephropathyDiabetic Nephropathy Type 2
Phase 2
Safety and Efficacy of Atrasentan in Men With Hormone Naive Prostate Cancer Exhibiting Early Signs of Biochemical Failure
CompletedNCT00038662
Start: 2002-05-31Target: 200Updated: 2006-08-15
A Long Term Safety Study With Atrasentan
CompletedNCT00127478
Start: 2001-07-31End: 2007-06-30Updated: 2007-11-29
Atrasentan and Zometa for Men With Prostate Cancer Metastatic to Bone
CompletedNCT00181558
Start: 2001-12-31End: 2006-12-31Target: 44Updated: 2010-05-10
Evaluate the Efficacy and Safety of Once Daily Administration of Atrasentan Tablets (Low and High) Compared to Placebo in Reducing Residual Albuminuria in Type 2 Diabetic Patients With Nephropathy Who Are Treated With the Maximum Tolerated Labeled Dose of a Renin Angiotensin System (RAS) Inhibitor
CompletedNCT01356849
Start: 2011-04-30End: 2012-08-31Updated: 2013-08-28
A Prospective, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate Efficacy and Safety of Atrasentan, Including Thoracic Bioimpedance, in Type 2 Diabetic Subjects With Nephropathy
CompletedNCT01399580
Start: 2011-08-31End: 2012-09-30Updated: 2013-10-25
Atrasentan Spermatogenesis and Testicular Function
CompletedNCT02118714
Start: 2015-04-06End: 2018-07-16Updated: 2019-05-07
Atrasentan in Patients With Proteinuric Glomerular Diseases
Active, not recruitingNCT04573920
Start: 2021-03-15End: 2026-10-27Updated: 2026-06-01
Randomized, Double-blind, Placebo-controlled, Crossover Study of Atrasentan in Subjects With IgA Nephropathy
CompletedNCT05834738
Start: 2023-07-20End: 2025-10-29Updated: 2026-07-20
A Randomized, Double-blind, Placebo-controlled, Crossover Study of Atrasentan in Subjects with IgA Nephropathy on Sodium-glucose Cotransporter-2 Inhibitors (SGLT2i) (The ASSIST study)
CompletedCTIS2023-503828-13-00
Start: 2023-12-12End: 2025-08-06Target: 10Updated: 2025-11-07
Phase 3
A Study of Atrasentan in Men With Metastatic, Hormone-Refractory Prostate Cancer
CompletedNCT00036543
Start: 2001-05-31Target: 1000Updated: 2006-08-15
Study of Atrasentan in Men With Non-Metastatic, Hormone-Refractory Prostate Cancer
CompletedNCT00036556
Start: 2001-06-30Updated: 2007-08-15
Correlation of Endothelial Function and Early Coronary Artery Disease in Humans
CompletedNCT00271492
Start: 2001-07-31End: 2008-01-31Updated: 2010-04-30
Correlation of Endothelial Function and Early Coronary Artery Disease in Humans
CompletedNCT00271492
Start: 2001-07-31End: 2008-01-31Updated: 2010-04-30
Study Of Diabetic Nephropathy With Atrasentan
TerminatedNCT01858532
Start: 2013-05-17End: 2018-03-29Updated: 2019-04-24
Atrasentan in Patients With IgA Nephropathy
Active, not recruitingNCT04573478
Start: 2020-12-11End: 2028-04-14Updated: 2026-06-04
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Atrasentan in Patients with IgA Nephropathy at Risk of Progressive Loss of Renal Function (The ALIGN Study)
Active, not recruitingCTIS2024-513227-16-00
Start: 2021-05-19Target: 42Updated: 2026-01-26
A single-arm, multicenter, phase III study to assess efficacy, pharmacokinetics, safety and tolerability of atrasentan in pediatric patients of 2 to <18 years of age with primary immunoglobulin A nephropathy (IgAN)
Not yet recruitingCTIS2025-522824-29-00
Target: 5Updated: 2026-08-10